Takeuchi Masato, Kano Hirotsugu, Takahashi Kenzo, Iwata Tsutomu
Department of Pediatrics, Kikkoman General Hospital, Noda, Chiba, Japan.
Department of Pediatrics, Teikyo University School of Medicine University Hospital-Mizonokuchi, Kawasaki, Kanagawa, Japan.
BMJ Open. 2015 Oct 22;5(10):e008501. doi: 10.1136/bmjopen-2015-008501.
Use of inhaled corticosteroid (ICS) is the mainstream maintenance therapy for paediatric asthma. Several forms of ICS are available, but the relative effectiveness among ICS has not been well investigated in published, randomised, controlled trials. The paucity of direct comparisons between ICS may have resulted in insufficient estimation in former systematic reviews/meta-analyses. To supplement the information on the comparative effectiveness of ICS for paediatric asthma, we plan to conduct a network meta-analysis that will enable summary of direct and indirect evidence.
We will retrieve randomised, controlled trials that examined the effectiveness of ICS for paediatric asthma from the PubMed and Cochrane Central Register of Controlled Trials. After one author scans the title and abstract for eligible studies, two authors will independently review study data and assess the quality of the study. Studies of children (≤18 years old) with chronic asthma or recurrent wheezing episodes will be included if they used ICS for ≥4 weeks. We will define a priori core outcomes and supplemental outcomes of paediatric asthma, including exacerbation, healthcare use and pulmonary function. Studies reporting a minimum of one core outcome will be entered into the systematic review. After the systematic review is performed, extracted data of relevant studies will be synthesised in the Bayesian framework using a random-effects model.
The results will be disseminated through peer-reviewed publications and conference presentations.
UMIN (000016724) and PROSPERO (CRD42015025889).
吸入性糖皮质激素(ICS)的使用是儿童哮喘的主流维持治疗方法。有多种形式的ICS可供选择,但在已发表的随机对照试验中,ICS之间的相对有效性尚未得到充分研究。ICS之间缺乏直接比较可能导致先前的系统评价/荟萃分析估计不足。为补充关于ICS治疗儿童哮喘比较有效性的信息,我们计划进行一项网络荟萃分析,以汇总直接和间接证据。
我们将从PubMed和Cochrane对照试验中央注册库中检索检验ICS治疗儿童哮喘有效性的随机对照试验。在一位作者浏览标题和摘要以筛选符合条件的研究后,两位作者将独立审查研究数据并评估研究质量。患有慢性哮喘或反复喘息发作的儿童(≤18岁)的研究,如果使用ICS≥4周将被纳入。我们将预先定义儿童哮喘的核心结局和补充结局,包括病情加重、医疗保健利用和肺功能。报告至少一项核心结局的研究将纳入系统评价。在进行系统评价后,将使用随机效应模型在贝叶斯框架下综合相关研究的提取数据。
研究结果将通过同行评审出版物和会议报告进行传播。
UMIN(000016724)和PROSPERO(CRD42015025889)。